Brian P. Weiser, Ph.D.

Associate Professor

Science Center 307A
Phone: 856 566-6270; Fax: 856 566-6291
weiser@rowan.edu 

Education

Johns Hopkins University, Baltimore, MD
Postdoc (Pharmacology / Enzymology)

University of Pennsylvania, Philadelphia, PA
Ph.D. (Pharmacology)

Albright College, Reading, PA
B.S. (Biology)

Research Interests

The Weiser Lab has several interests: (1) Understanding molecular mechanisms of protein activity regulation; (2) Discovering small molecules that can be used therapeutically or to explore protein function; (3) Developing statistical tools to understand non-canonical dose-response relationships.

Our projects examine DNA repair proteins, sirtuin deacylases, and various macromolecular complexes. We use traditional biochemistry methods along with computational, structural, and statistical modeling.

Keywords: uracil DNA glycosylase (UNG2), sirtuin isoform 2 (SIRT2), proliferating cell nuclear antigen (PCNA), replication protein A (RPA), propofol, fluorescence, hormesis, 1-aminoanthracene, dose-response

We welcome all opportunities to collaborate with other research groups to share our technical and material resources!

For a full publication list, visit this URL:
https://www.ncbi.nlm.nih.gov/myncbi/brian.weiser.1/bibliography/public/  

 

Selected Publications 

(1) Levy N, Salomon VL, Greenwood SN, Wang M, Kessler N, Erez O, Weiser BP, Afek A (2026) Mapping DNA glycosylase binding across lesion sequence contexts reveals extended sequence and structural recognition logic. Nature Communications (https://doi.org/10.1038/s41467-026-74090-0).

(2) Dispensa AN, Greenwood SN, Yang J, Logatto DE, Fusco J, White ER, Eckenhoff RG, Liu Z, Weiser BP (2026) Biophysical insights into a cryptic ligand site in the hydrophobic core of human PCNA. Biophysical Journal 125: 1-18.

(3) Kulkarni RS, Weiser BP (2026) Efficient activity of uracil DNA glycosylase (UNG2) in proliferating cells requires binding to proliferating cell nuclear antigen (PCNA) and replication protein A. DNA Repair 157: 103918.

(4) Greenwood SN, Dispensa AN, Wang M, Bauer JR, Vaden TD, Liu Z, Weiser BP (2025) Ion-DNA interactions as a key determinant of uracil DNA glycosylase activity. Biochemistry 64: 2332-2344.

(5) Yang J, Cassel J, Boyle BC, Oppong D, Ahn YH, Weiser BP (2024) A homogeneous time-resolved fluorescence screen to identify SIRT2 deacetylase and defatty-acylase inhibitors. PLOS ONE 19: e0305000.

(6) Yang J, Nicely NI, Weiser BP (2023) Effects of dimerization on the deacylase activities of human SIRT2. Biochemistry 62: 3383-3395.

(7) Abbaraju VD, Robinson TL, Weiser BP (2023) Modeling biphasic, non-sigmoidal dose-response relationships: comparison of Brain-Cousens and Cedergreen models for a biochemical dataset. ArXiv doi.org/10.48550/arXiv.2308.08618.

(8) Greenwood SN, Kulkarni RS, Mikhail M, Weiser BP (2023) Replication protein A enhances kinetics of uracil DNA glycosylase on ssDNA and across DNA junctions: explored with a DNA repair complex produced with SpyCatcher/SpyTag ligation. ChemBioChem 24: e202200765.

(9) Hong JY, Cassel J, Yang J, Lin H, Weiser BP (2021) High-throughput screening identifies ascorbyl palmitate as a SIRT2 deacetylase and defatty-acylase inhibitor. ChemMedChem 16: 3484-3494.

(10) Bi D, Yang J, Hong JY, Parikh P, Hinds N, Infanti J, Lin H, Weiser BP (2020) Substrate-dependent modulation of SIRT2 by a fluorescent probe, 1-aminoanthracene. Biochemistry 59: 3869-3878.